Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024752 | 0.86 | MEN1 (0.52) | L3MBTL1PTGS2MEN1KMT2APKM | |
| SCHEMBL3030118 | 0.85 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2AHTTUSP2 | |
| SCHEMBL3026333 | 0.80 | PTGS2 (0.78) | PTGS2ALDH1A1 | |
| SCHEMBL7215254 | 0.80 | PTGS2 (0.78) | PTGS2ALDH1A1 | |
| SCHEMBL3026121 | 0.79 | CHRNA7 (0.60) | PTGS2CHRNA7 | |
| SCHEMBL5314020 | 0.79 | CHRNA7 (0.60) | PTGS2CHRNA7 | |
| SCHEMBL3032641 | 0.79 | MCOLN3 (0.46) | PTGS2MEN1KMT2APKMUSP2 | |
| SCHEMBL5249795 | 0.78 | L3MBTL1 (0.86) | L3MBTL1MEN1KMT2AHTTUSP2 | |
| SCHEMBL5251337 | 0.78 | L3MBTL1 (0.86) | L3MBTL1MEN1KMT2AHTTUSP2 | |
| SCHEMBL3031646 | 0.78 | CA12 (0.58) | PTGS2MEN1KMT2APKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| CN-101479241-A | Pyrrole derivatives and their methods of use | ABBOTT LAB (US) | 2009-07-08 | — | — | CN | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | L3MBTL1 4423/4885PTGS2 69/4885MEN1 2853/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | L3MBTL1 4423/4885PTGS2 69/4885MEN1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.